Funding round
Abcuro Series D
Abcuro, which works in biopharmaceutical research and development in Newton, raised $66M in a Series D round announced on 18 Aug 2026, led by New Leaf Venture Partners. 15 firms took part, 13 of them already investors, with 2 individual investors. It is Abcuro's fourth venture round on record; the one before was a Series C in Feb 2025.
$66M
Amount raised
Not disclosed
Post-money valuation
15
Investors
1 lead
Valuation
What this round says about the price
Abcuro did not disclose a valuation in this round. It came 18 months after Abcuro's Series C. It is 14% of the $463M Abcuro has raised in the venture rounds on record. No later venture round is on record for Abcuro.
Abcuro's funding rounds
Abcuro has 4 venture rounds on record. This one is highlighted.
Investors
Who put money in
New Leaf Venture Partners led the round with 14 other firms. abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital and Redmile Group and 9 more had backed Abcuro before.
Lead investor
- backs 19 venture-backed companies new investor
Also in the round
- abrdn Inc. existing investor
- Bain Capital Life Sciences existing investor
- Samsara BioCapital existing investor
- Redmile Group existing investor
- Mass General Brigham Ventures existing investor
- backs 109 venture-backed companies existing investor
- backs 19 venture-backed companies existing investor
- Sanofi Ventures existing investor
- backs 39 venture-backed companies existing investor
- New Enterprise Associates backs 286 venture-backed companies existing investor
- Eurofarma Ventures existing investor
- backs 18 venture-backed companies existing investor
- Soleus Capital existing investor
- backs 20 venture-backed companies new investor
Individual investors: Nancy Chang and Shang Bay.
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
13 Series D rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $115M, and this round was 57% of the median. The closest in time, other companies' Series D rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| AdvanCell Pharmaceutical Products | 15 Jul 2026 | $315M | not disclosed | Ally Bridge Group and Alpha Wave Global |
| Pharmaceutical Products | 19 Oct 2026 | $135M | not disclosed | M Ventures and Revelation Partners |
| Pharmaceutical Products | 11 Jun 2026 | $47M | not disclosed | 太平医疗健康基金 and 上海科创集团 |
| Pharmaceutical Products | 18 May 2026 | $150M | not disclosed | Vivo Capital |
| Pharmaceutical Products | 9 Apr 2026 | $50M | not disclosed | Boehringer Ingelheim |
| Pharmaceutical Products | 25 Mar 2026 | $32M | not disclosed | Elev8 Venture Partners |
| Pharmaceutical Products | 5 Feb 2026 | $130M | not disclosed | Frazier Life Sciences and Venrock |
| Pharmaceutical Products | 22 Jan 2026 | $287M | not disclosed | not named |
Sources
Where this comes from
Reported by 5 sources. The deal data marks this round as not yet confirmed by an official announcement. Unconfirmed
Questions
Frequently asked
How much did Abcuro raise in its Series D round?
Abcuro raised $66M in its Series D round, announced in Aug 2026.
Who led Abcuro's Series D round?
New Leaf Venture Partners led it, with abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group and Mass General Brigham Ventures and 9 more.
What was Abcuro's valuation at the Series D round?
It was not disclosed.
How does it compare with other Series D rounds in Pharmaceutical Products?
13 Series D rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $115M, and this round was 57% of the median.